NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.2 Drugs affecting the immune response > 8.2.3 Anti-lymphocyte monoclonal antibodies > Lymphoma (follicular non-Hodgkin's) - rituximab NICE TAG TA137

Lymphoma (follicular non-Hodgkin's) - rituximab NICE TAG TA137

1.1 Rituximab, within its marketing authorisation, in combination with chemotherapy, is recommended as an option for the induction of remission in people with relapsed stage III or IV follicular non-Hodgkin's lymphoma.

1.2 Rituximab monotherapy as maintenance therapy, within its marketing authorisation, is recommended as an option for the treatment of people with relapsed stage III or IV follicular non-Hodgkin's lymphoma in remission induced with chemotherapy with or without rituximab.

1.3 Rituximab monotherapy, within its marketing authorisation, is recommended as an option for the treatment of people with relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma, when all alternative treatment options have been exhausted (that is, if there is resistance to or intolerance of chemotherapy).

https://www.nice.org.uk/guidance/TA137

Site by Devopa
© Copyright 2020 NHS. All rights reserved.